Monoclonal Antibodies
Galderma’s Nemluvio Secures Dual EU Approvals for Atopic Dermatitis and Prurigo Nodularis
Nemluvio, nemolizumab, Galderma, European Commission approval, atopic dermatitis, prurigo nodularis, IL-31 receptor alpha, monoclonal antibody
Marea Therapeutics Announces Breakthrough Phase II Results for MAR001, a Novel Monoclonal Antibody Targeting Remnant Cholesterol
Marea Therapeutics, MAR001, Remnant Cholesterol, Monoclonal Antibody, Cardiovascular Disease, ANGPTL4, Phase II Clinical Trial
Ikena Oncology and Inmagene Biopharmaceuticals Announce Merger to Advance Development of Atopic Dermatitis Treatment
Ikena Oncology, Inmagene Biopharmaceuticals, Merger, Atopic Dermatitis, IMG-007, Monoclonal Antibody, OX40, Biopharmaceuticals, Clinical Stage, Private Placement
Genmab Exercises Option for Second Commercial License Agreement with Scancell Holdings
Genmab, Scancell Holdings, monoclonal antibody, GlyMab platform, licensing agreement, cancer treatment, immunotherapies
Kinevant Sciences Discontinues Namilumab Development for Pulmonary Sarcoidosis Following Phase 2 Failure
Namilumab, Pulmonary Sarcoidosis, Phase 2 Study, Kinevant Sciences, RESOLVE-Lung Study, Anti-GM-CSF Monoclonal Antibody
Breakthroughs in RSV Prevention: Merck and Pfizer Report High Efficacy Rates
RSV prevention, Merck, Pfizer, clesrovimab, ABRYSVO, respiratory syncytial virus, monoclonal antibodies, vaccines
Merck’s Clesrovimab Shows Promising Results in Preventing RSV Disease and Hospitalizations in Infants
Clesrovimab, Respiratory Syncytial Virus (RSV), RSV Disease Prevention, Infant Health, Monoclonal Antibody, Clinical Trials, Merck & Co.
Enhanced Manufacturing Efforts by Sanofi and AstraZeneca Aim to Prevent Beyfortus Shortfalls in 2024
Beyfortus, RSV prevention, monoclonal antibody, Sanofi, AstraZeneca, manufacturing efforts, supply chain management
GSK’s Nucala Demonstrates Efficacy in COPD with Positive Phase III Trial Results
GSK, Nucala, COPD, Phase III trial, mepolizumab, chronic obstructive pulmonary disease, asthma, IL-5 antagonist, monoclonal antibody.
Vir Biotechnology Lays Off 25% of Staff, Shifts Focus to Cancer Research in Sanofi Partnership
Vir Biotechnology, layoffs, Sanofi partnership, cancer research, monoclonal antibodies